siRNA therapeutics for inflammation (Galena Biopharma)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamesiRNA therapeutics for inflammation (Galena Biopharma)
Drug Alias NamesiRNA therapeutics for inflammation (RXi Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 4 inhibitorsTumor necrosis factor inhibitors
TargetsMitogen-activated protein kinase kinase kinase kinase 4Tumor necrosis factor
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Massachusetts Medical School
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSellas Life Sciences Group Inc
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A